Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
Study Details
Study Description
Brief Summary
To evaluate if intravenous PPI infusion, when administered prior to endoscopy, hastens resolution of bleeding stigmata and thereby facilitates endoscopic examinations and reduces the need for endoscopic treatment. Clot stabilization may itself sustain control of bleeding before endoscopy. These may translate into improved patients'outcome and survival.
To determine the therapeutic effect of high-dose PPI infusion in upper gastrointestinal bleeding from causes other than peptic ulcers.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 4 |
Detailed Description
A placebo-controlled randomised study is being proposed. We hypothesize that early administration of intravenous omeprazole infusion stabilizes clots overlying arteries and hastens resolution of bleeding stigmata in peptic ulcer, and facilitates subsequent endoscopic examinations and reduces the need for endoscopic treatment. This may translates into clinical benefits in those who receive early intravenous omeprazole.
Consecutive patients with overt signs of upper gastrointestinal bleeding will be randomised to receive omeprazole or its equivalent placebo (80mg i.v. bolus followed by 8mg/hr) until next scheduled endoscopy. Patients with circulatory instability or fresh hematemesis will undergo endoscopic examinations urgently after initial stabilisation. The infusion will continue until endoscopic examination with or without therapy. Next scheduled endoscopy is performed within 24 hours from admission by experienced endoscopists with expertise in therapeutic endoscopy. At endoscopy, actively bleeding ulcers or ulcers with non-bleeding visible vessels are to be treated by endoscopic therapy. Omeprazole infusion 8mg/hr is to be continued for 72 hours after endoscopic hemostasis.
Patients will be followed-up for 30 days from the time of admission or if patients stay longer than 30 days, the time to hospital discharge or death.
Study Design
Outcome Measures
Primary Outcome Measures
- early intranvenous infusion of a high-dose poton-pump inhibitor before endoscopy would have a therapeutic effect on bleeding ulcers, reduce the need for endoscopic therapy, and result in improved clinical outcomes. []
Secondary Outcome Measures
- Control of bleeding (absence of active bleeding) at the time of endoscopic procedure []
- The prevalence of stigmata of bleeding at endoscopic examination []
- 30-day survival []
- Hospital stay []
- Transfusion requirement []
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients with overt signs of upper GIB; fresh hematemesis and/or melena with or with circulatory compromise
Exclusion Criteria:
-
Chronic aspirin user,
-
Pregnancy,
-
Age<16,
-
Allergy to PPI,
-
No consent
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Endoscopy Center, Prince of Wales Hospital | Hong Kong SAR | China |
Sponsors and Collaborators
- Chinese University of Hong Kong
Investigators
- Principal Investigator: James Y Lau, MD, Endoscopy Center, Prince of Wales Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- APPE